Labanimal

It's the December episode of 3-Minute 3Rs, brought to you by , the NC3Rs (www.nc3rs.org.uk), the North American 3Rs Collaborative (www.na3rsc.org) and Lab Animal (www.nature.com/laban) The papers behind the pod: 1. Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response https://bit.ly/2GwGJ7N 2. An In Vitro Model of Hematotoxicity https://bit.ly/2Ezgaw3 3. Found In Translation https://go.nature.com/2UVJ0g6 [NC3Rs] Every cancerous tumor is different and treating two tumors with the same drug may result in two very different outcomes, which contributes to the high failure rate during cancer drug discovery. One experiment type gaining interest to model this tumor heterogeneity is screening a population of patient-derived tumor xenograft models, or PDX models. However, there is little guidance available for these experiments. This risks poor experimental design that could result in a study being under or overpowered. Both these scenarios waste animal